Jul 29, 2019 17:49 JST

Source: NEC Corporation

NEC Acquires Norwegian Bioinformatics Company, OncoImmunity AS

TOKYO, Jul 29, 2019 - (JCN Newswire) - NEC Corporation (TSE: 6701) has announced the acquisition of OncoImmunity AS, a Norway-based bioinformatics company that develops proprietary machine learning software to support the fight against cancer. OncoImmunity AS will now become a subsidiary of NEC and operate under the name of NEC OncoImmunity AS.

OncoImmunity AS, founded in 2014, is a bioinformatics company dedicated to the development of software solutions that facilitate the effective selection of patients for cancer immunotherapy, and identify optimal neoantigen targets for truly personalized cancer vaccines and cell therapies in a clinically actionable time frame.

NEC announced its business strategy surrounding its AI-driven drug discovery business in May 2019. This acquisition is integral for enhancing the resources and capabilities that support the development of its individualized immunotherapy pipelines. NEC will maintain its focus on drug discovery, while NEC OncoImmunity AS continues its neoantigen prediction services.

Sharing a common vision, both NEC and OncoImmunity AS firmly believe in improving individualized cancer treatments through Artificial Intelligence (AI). AI holds great promise in enabling each and every patient to receive the most appropriate medication.

"The OncoImmunity AS team are delighted to be joining the NEC Group and firmly believe that the union will realize great synergies, marrying the mutual strengths of OncoImmunity AS's and NEC's neoantigen prediction pipelines with NEC's expertise in AI, data management and security. These synergies will help strengthen NEC's individualized immunotherapy programs, whilst simultaneously positioning NEC OncoImmunity AS as the leading neoantigen prediction service provider in the field," said Dr. Richard Stratford, Chief Executive Officer and Co-founder of OncoImmunity AS.

"NEC strongly believes that healthcare based on genomics paves the way for individualized medicine. OncoImmunity AS is a recognized player in the neoantigen prediction field, and their compelling systems are expected to form valuable synergies with NEC. We are confident that this acceleration of development will provide promising new avenues that lead to better cancer treatments," said Osamu Fujikawa, Senior Vice President, NEC Corporation.

Contact:
NEC 
Seiichiro Toda         
s-toda@cj.jp.nec.com 
+81-3-3798-6511
Source: NEC Corporation
Sectors: CyberSecurity

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


NEC Develops Physical AI That Anticipates Human Movement and Psychological States
March 12 2026 15:41 JST
 
NEC and The University of Tokyo calculate carbon accumulation rates in Malaysian national park with a 9.4% margin of error
March 12 2026 11:02 JST
 
DOCOMO and NEC Launch Japan's First Commercial 5G Core on AWS, Built with World's First AI-automated Network Construction Technology
March 02 2026 15:34 JST
 
NEC Strengthens Multi-Vendor Optical Network Solutions with New TIP-Certified Phoenix Hardware Lineup
February 27 2026 17:50 JST
 
NEC Demonstrates Agentic AI-Driven Autonomous Network Operations in Collaboration with AWS
February 27 2026 16:31 JST
 
NEC Strengthens Its Edge Portfolio for the 6G Era, Enabling Efficient Edge Deployment and Integration with Cloud Services
February 27 2026 11:24 JST
 
The University of Tokyo, NTT, and NEC demonstrate real-time augmented reality assistance made possible by integrating three newly proposed technologies on a 6G/IOWN platform to realize the widespread use of AI agents supporting safety and security
February 26 2026 18:01 JST
 
NEC and Nokia to Expand Eletronet's Optical Fiber Network in Brazil by 50%
February 26 2026 17:51 JST
 
NEC Implements AI Code Review Service "Metabob," Reducing Technical Verification Time by Up to 66%
February 25 2026 17:00 JST
 
NEC Exhibits at MWC Barcelona 2026, the World's Largest Mobile-Related Exhibition
February 09 2026 20:18 JST
 
More Press release >>

Latest Press Release


More Latest Release >>